Seeking Alpha
 

ZIOPHARM Oncology, Inc. (ZIOP)

- NASDAQ
  • Oct. 31, 2014, 12:49 PM
    • ZIOPHARM Oncology (ZIOP +7.8%Q3 results: Revenues: $633K (+216.5%); R&D Expense: $9.7M (+56.5%); SG&A: $2.8M (-9.7%); Operating Loss: $(11.9M) (-30.8%); Net Loss: $(6.1)M (+63.5%); EPS: $-0.06 (+70.0%); Quick Assets: $46.1M (-32.4%).
    • No guidance given.
    | 1 Comment
  • Oct. 30, 2014, 4:11 PM
    • ZIOPHARM Oncology (NASDAQ:ZIOP): Q3 EPS of -$0.06 may not be comparable to consensus of -$0.12.
    • Revenue of $0.6M (+200.0% Y/Y) misses by $2.83M.
    • Press Release
    | Comment!
  • Aug. 7, 2014, 6:22 PM
    • Ziopharm Oncology (ZIOP -4.3%) Q2 results: Revenues: $200K (unch); Operating Loss: ($11.2M) (+38.9%); Net Loss: ($5.6M) (+70.2%); Loss Per Share: ($0.06) (+72.7%); Quick Assets: $53.0M (-22.3%).
    • No guidance given.
    | Comment!
  • Aug. 7, 2014, 4:18 PM
    • ZIOPHARM Oncology (NASDAQ:ZIOP): Q2 EPS of -$0.06 may not be comparable to consensus of -$0.13.
    • Revenue of $0.2M (flat Y/Y) misses by $2.43M.
    • Press Release
    | Comment!
  • May. 14, 2014, 5:35 PM
  • Mar. 3, 2014, 4:48 PM
    • ZIOPHARM Oncology, Inc. (ZIOP): Q4 EPS of -$0.09 beats by $0.06.
    • Revenue of $200K.
    • Press Release
    | Comment!
  • Oct. 22, 2013, 6:00 PM
    • Ziopharm (ZIOP): Q3 EPS of -$0.20 misses by $0.02.
    • Revenue of $200K in-line. Shares -3.3% AH. (PR)
    | Comment!
  • Aug. 8, 2013, 4:53 PM
    • Ziopharm (ZIOP): Q2 EPS of -$0.22 beats by $0.02.
    • Revenue of $200K in-line. (PR)
    | Comment!
  • May. 7, 2013, 7:30 PM
    Ziopharm (ZIOP): Q1 EPS of -$0.15 beats by $0.12. Revenue of $200K beats by $40.K. (PR)
    | Comment!
  • Mar. 18, 2013, 4:49 PM
    More on Ziopharm (ZIOP): Q4 comes in-line on revenue but misses on a per shares basis. Operating expenses rose 134% over the prior year, primarily due to an $18.7M non-cash expense associated with the issuance of approximately 3.6M shares of common stock to Intrexon as a milestone payment associated with the dosing of the first patient in its Ad-RTS IL-12 Phase 2 trial. Shares -2% AH.
    | Comment!
  • Mar. 18, 2013, 4:22 PM
    Ziopharm (ZIOP): Q4 EPS of -$0.37 misses by $0.08. Revenue of $200K beats by $30K. Shares -1.1% AH. (PR)
    | Comment!
  • Aug. 2, 2012, 6:56 PM
    ZIOPHARM Oncology (ZIOP): Q2 EPS of -$0.29 misses by $0.06. Revenue of $200K (flat% Y/Y) beats by $50K. (PR)
    | Comment!
  • Feb. 29, 2012, 5:30 PM
    Ziopharm Oncology (ZIOP): Q4 EPS of -$0.24 misses by $0.01. Revenue of $0.2M. Shares -2.4% AH. (PR)
    | Comment!
ZIOP vs. ETF Alternatives
Company Description
ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of small molecule and synthetic biology approaches to cancer therapies.
Sector: Healthcare
Industry: Biotechnology
Country: United States